Crossmark

The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases

Crossref DOI link: https://doi.org/10.1186/s12879-017-2665-5

Published Online: 2017-08-09

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yagi, Kazuma

Ishii, Makoto https://orcid.org/0000-0003-4396-1664
Namkoong, Ho

Asami, Takahiro

Iketani, Osamu

Asakura, Takanori

Suzuki, Shoji

Sugiura, Hiroaki

Yamada, Yoshitake

Nishimura, Tomoyasu

Fujiwara, Hiroshi

Funatsu, Yohei

Uwamino, Yoshifumi

Kamo, Tetsuro

Tasaka, Sadatomo

Betsuyaku, Tomoko

Hasegawa, Naoki